atezolizumab plus pemetrexed and platin (n=292) vs. pemetrexed plus platin (n=286)
randomized controlled trial
Atezolizumab (induction and maintenance) plus pemetrexed plus platine
Atezolizumab 1200 mg IV every 3 weeks plus carboplatin or cisplatin (Carboplatin: AUC 6 mg/mL/min IV q3w; Cisplatin: 75 mg/m2 IV q3w) plus pemetrexed (500 mg/m2 IV q3w) for 4 or 6 cyclesb for induction and permetrexed maintenance therapy
pemetrexed plus platine
carboplatin or cisplatin (Carboplatin: AUC 6 mg/mL/min IV q3w; Cisplatin: 75 mg/m2 IV q3w) plus pemetrexed (500 mg/m2 IV q3w) for 4 or 6 cyclesb for induction and permetrexed maintenance therapy
non squamous - mNSCLC - L1 - Wild Type (WT)
open-label
NA
P3
IMpower132 met its co-primary endpoint of investigator-assessed PFS in the ITT population but preliminary results on OS were not significant (IA)